ISIS Pharmaceuticals Inc $37.00

down 0.00


22/4/2014 08:10 PM  |  NASDAQ : ISIS  
Industries : Drugs / Drug Manufacturers - Other
Get Trend Analysis Icon Get ISIS Trend Analysis - it has outperformed the S&P 500 by 49%

Partner Headlines

  1. Isis Pharmaceuticals to Present ISIS-SMN Rx Data at 2014 AAN Annual Meeting

    Benzinga
  2. Isis Reports Final Phase 2 Data on ISIS-APOCIII Rx

    Benzinga
  3. EARLIER: Isis Announces Antisense Targeting of HBV Produces Dose-Dependent ...

    Benzinga
  4. BioMed Realty Trust Leases Space To Life Science Firms

    IBD
  5. US Stock Futures Edge Higher; All Eyes On Fed

    Benzinga
  6. US Stock Futures Tumble Ahead Of Economic Data

    Benzinga
  7. Earnings Scheduled For February 28, 2014

    Benzinga
  8. Mid-Afternoon Market Update: Groupon Shares Continue to Show Weakness Following ...

    Benzinga
  9. Mid-Day Market Update: Acacia Research Shares Decline On Downbeat Results; ...

    Benzinga
  10. US Stock Futures Rise Ahead Of Existing-Home Sales Data

    Benzinga
  11. Isis Pharmaceuticals Earns $2M Milestone Payment from GSK for Advancement ...

    Benzinga
  12. UPDATE: Piper Jaffray Assumes Coverage on ISIS Pharmaceuticals as Company's ...

    Benzinga
  13. Isis Pharmaceuticals Initiates Phase 1 Study of ISIS-GSK3 Rx, Earns $3M ...

    Benzinga
  14. Isis Pharmaceuticals Announces Plan Investigate Higher Dose of ISIS-SMN ...

    Benzinga
  15. Isis Pharmaceuticals Announces Fifth Positive Phase 2 Data Set for ISIS-APOCIII ...

    Benzinga
  16. Isis Pharmaceuticals Announces Positive Phase 1 Results with ISIS-APO(a) ...

    Benzinga
  17. Isis Pharmaceuticals Announces $1.5M Milestone Payment from Biogen Related ...

    Benzinga
  18. UPDATE: J.P. Morgan Initiates Coverage on Isis Pharmaceuticals, Awaiting ...

    Benzinga
  19. Benzinga's Top Initiations

    Benzinga
  20. ISIS Pharm Advances Phase 2 Study of ISIS-SMN Rx in Infants, Says Earns ...

    Benzinga
  21. Pharmaceutical Industry Expected To Collect Billions From Obamacare

    Benzinga
  22. Market Wrap For Monday, September 23: Markets Unmoved Despite Kenyan Terror

    Benzinga
  23. Mid-Afternoon Market Update: Celldex Therapeutics Rallies as Pandora Drops

    Benzinga
  24. Mid-Day Market Update: Oil Futures Tumble For Third Day in a Row; BlackBerry ...

    Benzinga
  25. Isis Reports Positive Phase 2 Data on ISIS-APOCIII Rx in Patients with ...

    Benzinga
  26. Isis Reports Follow-Up Data from Phase 1 ISIS-SMN Rx SMA Study

    Benzinga
  27. Market Wrap for Monday, September 9: Nasdaq Bounces To 13 Year High

    Benzinga
  28. Mid-Afternoon Market Update: Markets Lead by the NASDAQ as Various Health ...

    Benzinga
  29. Mid-Day Market Update: Dow Rises Over 100 Points; Apple Shares Gain

    Benzinga
  30. Isis Pharma, Biogen Idec to Tackle Brain Disorders

    FoxBusiness
  31. Benzinga's Volume Movers

    Benzinga
  32. Mid-Morning Market Update: Markets Open Higher; Koch Industries To Acquire ...

    Benzinga
  33. Goldman Sachs Reiterates Neutral Rating, $26 PT on ISIS Pharmaceuticals ...

    Benzinga
  34. Benzinga's Top Pre-Market Gainers

    Benzinga
  35. US Stock Futures Up Ahead Of Consumer Credit Data

    Benzinga
  36. Benzinga's Top Initiations

    Benzinga
  37. Benzinga's Top Pre-Market Gainers

    Benzinga
  38. Isis Reports Positive Interim Phase 2 Data on ISIS-APOCIII Rx

    Benzinga
  39. These ETFs House The Next Biotech Takeover Targets

    Benzinga
  40. Barron's Recap: The Changing World Of MLPs

    Benzinga
  41. Isis Pharmaceuticals

    IBD
  42. Needham Says Buy the Dip in Isis Pharma, Didn't See Favorable Chance CRP ...

    Benzinga
  43. Isis Pharmaceuticals Reports Phase 2 Data from Isis-CRP Rx RA Study

    Benzinga
  44. $176,000 or $295,00 a Year: Bizarre World of Orphan Drugs

    YCharts
  45. Market Wrap for Wednesday, January 30: Stocks Fall as Economy Contracts ...

    Benzinga
  46. Mid-Day Market Update: BlackBerry 10 Release Sends Shares Lower, Isis Pharma ...

    Benzinga
  47. UPDATE: Jefferies Reiterates Underperform Rating, Raises PT on ISIS Pharmaceuticals

    Benzinga
  48. Isis Pharmaceuticals to Provide Update on FDA Approval of KYNAMRO, 09:3 ...

    Benzinga
  49. Isis Pharmaceuticals (ISIS) Chairman, CEO and President Stanley T Crooke ...

    GuruFocus
  50. UPDATE: BMO Capital Markets Reiterates Outperform Rating, Raises PT on ...

    Benzinga
Trading Center